Skip to main content

Table 3 Median time from specimen collection to treatment initiation, by diagnostic method and disease classification (n = 686)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

  Early cohort (n = 256) Late cohort (n = 430) P value
Diagnosis method
 Xpert MTB/RIF 17 (9–46) (n = 107) 13 (7–28) (n = 282) < 0.001
 GenoType MTBDRplus line probe assay 38 (23–51) (n = 129) 15 (7–36) (n = 129)  
 Phenotypic drug susceptibility testing 81 (28–97) (n = 7) n/a  
Disease classification
 RR-TB by Xpert MTB/RIF 13 (9–30) (n = 57) 10 (7–17) (n = 188) < 0.001
 RIF mono-resistant TB 48 (30–75) (n = 48) 13 (2–38) (n = 62)  
 MDR-TB 34 (14–49) (n = 147) 22 (8–37) (n = 128)  
 XDR-TB 42 (35–70) (n = 3) 36 (14–61) (n = 4)  
  1. MDR-TB Multi-drug resistant, XDR-TB Extensively drug resistant TB, RR-TB Rifampicin resistant TB, RIF rifampicin